BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Bogdana Schmidt
Absolutely. And like you said earlier, you know, we already had nivolumab approved before. So that's two positive trials in this space. We didn't really talk about Invigor, the earlier Atizo trial that didn't meet its primary endpoint, which could be related to the Atizo, could be related to where the trials were structured.
0
💬
0
Comments
Log in to comment.
There are no comments yet.